Pareek, M., Johansen, N. D., Modin, D., Pardo-Seco, J., Rodriguez-Tenreiro-Sánchez, C., Loiacono, M. M., Harris, R. C., Dufournet, M., van Aalst, R., Chit, A.
, Larsen, C. S., Larsen, L., Wiese, L., Dalager-Pedersen, M., Claggett, B. L., Janstrup, K. H., Duran-Parrondo, C., Piñeiro-Sotelo, M., Cribeiro-González, M. ... DANFLU-2 Study Group and GALFLU Trial Team (2026).
High-Dose Influenza Vaccination in Atherosclerotic Cardiovascular Disease: A Multinational Pooled Analysis of DANFLU-2 and GALFLU (FLUNITY-HD).
Journal of the American College of Cardiology,
87(11), 1374-1380.
https://doi.org/10.1016/j.jacc.2025.12.080Nielsen, A. B., Johansen, N. D., Modin, D., Loiacono, M. M., Harris, R. C., Dufournet, M.
, Larsen, C. S., Larsen, L., Wiese, L., Dalager-Pedersen, M., Claggett, B. L., Janstrup, K. H., Bartholdy, K. V., Bernholm, K. F., Borchsenius, J. I. M. H., Davidovski, F. S., Davodian, L. W., Dons, M., Duus, L. S. ... Biering-Sørensen, T. (2026).
High-Dose vs Standard-Dose Influenza Vaccine in Older Adults With Diabetes: A Secondary Analysis of the DANFLU-2 Randomized Clinical Trial.
JAMA Internal Medicine,
186(3).
https://doi.org/10.1001/jamainternmed.2025.7286Rezahosseini, O., Jensen, J. U. S., Rahimi, H. K., Jensen, N. E., Jørgensen, C. S., Fischer, T. K., Ostrowski, S. R., Lundgren, J.
, Ostergaard, L., Harboe, Z. B. & ENFORCE Study Group (2026).
Immunogenicity and Safety of the COVID-19 Messenger RNA Vaccine Coadministered With Influenza and 23-valent Pneumococcal Polysaccharide Vaccines.
Clinical Infectious Diseases,
82(2), e343-e351.
https://doi.org/10.1093/cid/ciaf455Larsen, F. D., Juhl, A. K., Dietz, L. L., Nielsen, H.
, Stærke, N. B., Johansen, I. S., Wiese, L., Benfield, T., Bodilsen, J.
, Klastrup, V., Lindvig, S. O., Rasmussen, L. D., Knudsen, L. S.
, Tolstrup, M., Østergaard, L. J., Lundgren, J.
, Søgaard, O. S., Larsen, C. S. & ENFORCE Study Group (2026).
Immunogenicity of SARS-CoV-2 primary vaccination and boosters in patients with immune-mediated inflammatory diseases: Impact of immunosuppressive therapy.
Vaccine,
73, Article 128155.
https://doi.org/10.1016/j.vaccine.2025.128155
Johannsen, I. M., Vibholm, L. K., Frattari, G. S., Rosas-Umbert, M., Tarpgaard, I. H., Storgaard, M., Juhl, A. K., Pedersen, M. L., Iversen, E. F., Andersen, N. B., Ebsen, T. S., Svensgaard, S. N. H., Andreas, M., Asdahl, P., Leth, S., Rasmussen, T. A., Schleimann, M. H. & Tolstrup, M. (2026).
Immunological Dysfunction Associated with SARS-CoV-2 Persistence in Immunocompromised Patients.
Clinical and Experimental Immunology, Supplement,
220(1), Article uxag022.
https://doi.org/10.1093/cei/uxag022
King, H. A. D., Angelovich, T. A., Moso, M. A.
, Pascoe, R. D., Churchill, M. J. & Lewin, S. R. (2026).
Immunotherapy and impact on tissue reservoirs.
Current Opinion in HIV and AIDS,
21(1), 31-39.
https://doi.org/10.1097/COH.0000000000000996Hønge, B. L., Redder, J.
, Greve, T., Dalgaard, L. S., Sørensen, A. R.
, Ebdrup, L., Mohey, R.
, Tarp, B., Holm, M., Østergaard, L. & Storgaard, M. (2026).
Implications of empirical testing and treatment for atypical bacteria in patients hospitalized with COVID, influenza, or RSV: a retrospective observational cohort study.
European Journal of Clinical Microbiology and Infectious Diseases,
45(4), 1157-1165.
https://doi.org/10.1007/s10096-026-05405-8